CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Vivo, I.
Right arrow Articles by Hunter, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Vivo, I.
Right arrow Articles by Hunter, D. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 489-492, May 2002
© 2002 American Association for Cancer Research

Short Communications

Association of CYP1B1 Polymorphisms and Breast Cancer Risk1

Immaculata De Vivo2, Susan E. Hankinson, Lisa Li, Graham A. Colditz and David J. Hunter

Departments of Epidemiology [I. D., S. E. H., G. A. C., D. J. H.] and Nutrition [D. J. H.], and the Harvard Center for Cancer Prevention [I. D., G. A. C., D. J. H.], Harvard School of Public Health, and the Channing Laboratory [I. D., S. E. H., L. L., G. A. C., D. J. H.], Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts 02115

Cytochrome P450 1B1 catalyzes the conversion of 17-ß-estradiol (E2) to thecatechol estrogen metabolites 2-OH-E2 and 4-OH-E2 that have been postulated to be involved in mammary carcinogenesis. We sought to determine whether two common functional polymorphisms in Cytochrome P450 1B1, V432L (m1), and A453S (m2) are related to breast cancer risk. Using a nested case control design within the Nurses’ Health Study cohort, we genotyped 453 cases and 456 controls and found no significant association between m1[val/leu and leu/leu versus val/val, OR = 1 (CI, 0.72–1.45)] or m2 [asn/ser and ser/ser versus asn/asn, OR = 0.8 (CI, 0.62–1.15)] and breast cancer risk. However, we did observe women with the Val/Val (m1) genotype to have a higher percentage of estrogen receptor-positive tumors (P = 0.03). We did not observe any correlation with the m2 genotypes and estrogen receptor status. The association of the m1 and m2 genotypes on plasma hormone levels in postmenopausal control women not using hormone replacement therapy was also evaluated. Carriers of the m1 leu and m2 ser alleles had modestly higher estradiol levels but similar estrone and estrone sulfate levels. The results presented do not support a strong association between m1 and m2 and the risk of breast cancer.




This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
V. Paracchini, S. Raimondi, I. T. Gram, D. Kang, N. A. Kocabas, V. N. Kristensen, D. Li, F. F. Parl, T. Rylander-Rudqvist, P. Soucek, et al.
Meta- and Pooled Analyses of the Cytochrome P-450 1B1 Val432Leu Polymorphism and Breast Cancer: A HuGE-GSEC Review
Am. J. Epidemiol., January 15, 2007; 165(2): 115 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. J. De Roos, N. Rothman, M. Brown, D. A. Bell, G. S. Pittman, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, and P. D. Inskip
Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors.
Neuro-oncol, April 1, 2006; 8(2): 145 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. E. Cribb, M. J. Knight, D. Dryer, J. Guernsey, K. Hender, M. Tesch, and T. M. Saleh
Role of polymorphic human cytochrome p450 enzymes in estrone oxidation.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 551 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
K. Visvanathan, L. Gallicchio, C. Schilling, J. K. Babus, L. M. Lewis, S. R. Miller, H. Zacur, and J. A. Flaws
Cytochrome Gene Polymorphisms, Serum Estrogens, and Hot Flushes in Midlife Women
Obstet. Gynecol., December 1, 2005; 106(6): 1372 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. S. Cicek, X. Liu, G. Casey, and J. S. Witte
Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11{alpha} in Prostate Cancer Risk and Aggressiveness
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2173 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Le Marchand, T. Donlon, L. N. Kolonel, B. E. Henderson, and L. R. Wilkens
Estrogen Metabolism-Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study
Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1998 - 2003.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L.A. Hefler, C. Grimm, G. Heinze, C. Schneeberger, M.W. Mueller, A. Muendlein, J.C. Huber, S. Leodolter, and C.B. Tempfer
Estrogen-metabolizing gene polymorphisms and age at natural menopause in Caucasian women
Hum. Reprod., May 1, 2005; 20(5): 1422 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. Wen, Q. Cai, X.-O. Shu, J.-R. Cheng, F. Parl, L. Pierce, Y.-T. Gao, and W. Zheng
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 329 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Bandiera, S. Weidlich, V. Harth, P. Broede, Y. Ko, and T. Friedberg
Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 Expression
Mol. Pharmacol., February 1, 2005; 67(2): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Rylander-Rudqvist, S. Wedren, G. Jonasdottir, S. Ahlberg, E. Weiderpass, I. Persson, and M. Ingelman-Sundberg
Cytochrome P450 1B1 Gene Polymorphisms and Postmenopausal Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1515 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. McGrath, S. E. Hankinson, L. Arbeitman, G. A. Colditz, D. J. Hunter, and I. De Vivo
Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility
Carcinogenesis, April 1, 2004; 25(4): 559 - 565.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhu, M. R. Spitz, C. I. Amos, J. Lin, M. B. Schabath, and X. Wu
An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology
Cancer Res., March 15, 2004; 64(6): 2251 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Tworoger, J. Chubak, E. J. Aiello, C. M. Ulrich, C. Atkinson, J. D. Potter, Y. Yasui, P. L. Stapleton, J. W. Lampe, F. M. Farin, et al.
Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Rylander-Rudqvist, S. Wedren, F. Granath, K. Humphreys, S. Ahlberg, E. Weiderpass, M. Oscarson, M. Ingelman-Sundberg, and I. Persson
Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk
Carcinogenesis, September 1, 2003; 24(9): 1533 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Gibson, J. H. Gill, P. A. Khan, J. M. Seargent, S. W. Martin, P. A. Batman, J. Griffith, C. Bradley, J. A. Double, M. C. Bibby, et al.
Cytochrome P450 1B1 (CYP1B1) Is Overexpressed in Human Colon Adenocarcinomas Relative to Normal Colon: Implications for Drug Development
Mol. Cancer Ther., June 1, 2003; 2(6): 527 - 534.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.